Q3 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Our pipeline projects at a glance Appendix Innovation: Clinical trials References Abbreviations Phase 1/2 Phase 3 Registration Total Oncology Solid tumors Hematology Immunology 28 11 2 41 16 4 1 21 12 7 1 20 19 11 2 32 Neuroscience 5 5 0 10 Cardiovascular 5 10 0 15 Others (thereof IB&GH) 13 (9) 2 (1) 0 15 70 39 4 113 IB&GH: In-market Brands and Global Health. 33 Investor Relations | Q3 2023 Results INNOVATION 1 NOVARTIS | Reimagining Medicine

View entire presentation